Abstract 3239: Drug-Eluting Stents for the Treatment of Very Long Coronary Artery Stenosis: A Comparison of Serial Angiographic Follow-Up with Sirolimus, Paclitaxel, Zotarolimus and Tacrolimus-Eluting Stent: Multicenter Registry in Asia
Background: Drug-eluting stents prevent coronary restenosis across wide range patients. However, no studies comparing the effect of different drug-eluting stents in patients with very long coronary lesion (VLL) (lesion length ≥40 mm). The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES), and Tacrolimus-eluting stent (TES) on the outcome of stenting in patients with VLL.
Methods: A prospective analysis of 788 patients with VLL (SES 368, PES 288, ZES 83, TES 49) in five high volume Asian centers after successful stenting was performed. The study endpoints were major adverse cardiac events (MACE), at 30 days, 9 months and restenosis and target lesion revascularization (TLR) at 9 months.
Results: The baseline clinical characteristics between 4 groups were similar. See table⇓ for clinical results.
The use of drug-eluting stents in patients with very long coronary lesions seems to be favorable in terms of in-hospital clinical outcome and long-term results.
Patients treated with SES showed lesser restenosis rate and TLR compared with other drug-eluting stents.